Brought to you by 
Novartis and Vernalis in cancer deal; alliance ends
30 Jan 2023
Executive Summary
The Novartis Institutes for Biomedical Research has licensed exclusive worldwide rights to Vernalis PLC's (oncology and neurology) Hsp90 cancer research program. The deal follows a six-month evaluation period entered into by the companies last year in which Novartis had the option to license rights to the project.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis and Vernalis in cancer deal; alliance ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice